Harvard Medical School Researcher Wins 2024 Lasker Award for …
Sep 19, 2024 · Harvard Medical School researcher Joel Habener has won the 2024 Lasker~DeBakey Clinical Medical Research Award for his discovery of glucagon-like peptide-1 (GLP-1), a molecule that has become the basis for therapies which have transformed the treatment of obesity.
Guidance issued for safe use of GLP-1 RAs in the perioperative …
7 hours ago · In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of glucagon-like peptide ...
FDA approves first oral GLP-1 treatment for type 2 diabetes
Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected.
Glucagon-like peptide-1 receptor: mechanisms and advances in …
Sep 18, 2024 · The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell...
Glucagon-like peptide-1 receptor agonists tied to lower risk for …
4 days ago · Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...
Special Report: Potential Strategies for Addressing GLP-1 and Dual …
Apr 7, 2023 · Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have persisted through the first quarter of 2023 .
Research shows GLP-1 drugs are effective but complex - UChicago …
May 30, 2024 · While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for weight management and Type 2 diabetes treatment.
Multisociety Clinical Practice Guidance for the Safe Use of Glucagon ...
Oct 29, 2024 · Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to the agonists’ unique combination of effects, including decreasing hyperglycemia and enhancement of satiety. 1,2 GLP-1, a naturally secreted polypeptide, acts on the GLP-1R in multiple organs, including the pancreas,...
Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis
Oct 30, 2024 · Abstract. Osteoarthritis is one of the world’s leading causes of disability. Roughly 4.3% of adults have painful knee osteoarthritis, with knee pain on most days 1; the prevalence of disease is ...
AstraZeneca licenses novel agent for the treatment of …
Nov 9, 2023 · AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions.